122 related articles for article (PubMed ID: 30461351)
1. Ciprofloxacin Promoted
Kocsis B; Szmolka A; Szabo O; Gulyas D; Kristóf K; Göcző I; Szabo D
Microb Drug Resist; 2019 May; 25(4):501-508. PubMed ID: 30461351
[No Abstract] [Full Text] [Related]
2. Type II and type IV topoisomerase mutations in clinical isolates of Morganella morganii harbouring the qnrD gene.
Nasri Yaiche M; Denden Rafraf I; Guo Q; Mastouri M; Aouni M; Wang M
Ann Clin Microbiol Antimicrob; 2014 Aug; 13():34. PubMed ID: 25106550
[TBL] [Abstract][Full Text] [Related]
3. Description and plasmid characterization of qnrD determinants in Proteus mirabilis and Morganella morganii.
Mazzariol A; Kocsis B; Koncan R; Kocsis E; Lanzafame P; Cornaglia G
Clin Microbiol Infect; 2012 Mar; 18(3):E46-8. PubMed ID: 22192340
[TBL] [Abstract][Full Text] [Related]
4. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
[TBL] [Abstract][Full Text] [Related]
5. Substitutions of Ser83Leu in GyrA and Ser80Leu in ParC Associated with Quinolone Resistance in Acinetobacter pittii.
Gu DX; Hu YJ; Zhou HW; Zhang R; Chen GX
Microb Drug Resist; 2015 Jun; 21(3):345-51. PubMed ID: 25514581
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of quinolone resistance determinant qnrA6 among broad- and extended-spectrum beta-lactam-resistant Proteus mirabilis and Morganella morganii clinical isolates with sul1-type class 1 integron association in a Tunisian Hospital.
Mahrouki S; Perilli M; Bourouis A; Chihi H; Ferjani M; Ben Moussa M; Amicosante G; Belhadj O
Scand J Infect Dis; 2013 Aug; 45(8):600-5. PubMed ID: 23746343
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and characterisation of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes among Shigella isolates from Henan, China, between 2001 and 2008.
Yang H; Duan G; Zhu J; Zhang W; Xi Y; Fan Q
Int J Antimicrob Agents; 2013 Aug; 42(2):173-7. PubMed ID: 23796894
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of fluoroquinolones and fluoroquinolone-resistance genes in the aquatic environment.
Adachi F; Yamamoto A; Takakura K; Kawahara R
Sci Total Environ; 2013 Feb; 444():508-14. PubMed ID: 23291652
[TBL] [Abstract][Full Text] [Related]
10. Description and plasmid characterization of the qnrD determinant in Proteeae in Wenzhou, Southern China.
Chen L; Zhang Y; Du J; Zhang X; Li M; Chen H; Yu X; Sun Y; Zhou T
J Microbiol Immunol Infect; 2018 Feb; 51(1):115-122. PubMed ID: 27049282
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
Zhou Y; Yu L; Li J; Zhang L; Tong Y; Kan B
Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
[TBL] [Abstract][Full Text] [Related]
12. Novel mutations in gyrA and parC among Shigella sonnei strains from Jiangsu Province of China, 2002-2011.
Gu B; Qin TT; Fan WT; Bi RR; Chen Y; Li Y; Ma P
Int J Infect Dis; 2017 Jun; 59():44-49. PubMed ID: 28392317
[TBL] [Abstract][Full Text] [Related]
13. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
Yang J; Luo Y; Cui S; Wang W; Han L
Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
[TBL] [Abstract][Full Text] [Related]
14. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
Turner AK; Nair S; Wain J
J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of gyrA Mutations in Nalidixic Acid-Resistant Strains of Salmonella Enteritidis Isolated from Humans, Food, Chickens, and the Farm Environment in Brazil.
Campioni F; Souza RA; Martins VV; Stehling EG; Bergamini AMM; Falcão JP
Microb Drug Resist; 2017 Jun; 23(4):421-428. PubMed ID: 27559761
[TBL] [Abstract][Full Text] [Related]
16. [Mutations of DNA gyrase and topoisomerase IV in clinical isolates of fluoroquinolone-resistant Proteus mirabilis].
Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
Jpn J Antibiot; 2006 Feb; 59(1):41-3. PubMed ID: 16673582
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Quinolone-Resistant Determinants in Tribe
Wimalasena SHMP; Pathirana HNKS; Shin GW; De Silva BCJ; Hossain S; Heo GJ
Microb Drug Resist; 2019 May; 25(4):611-618. PubMed ID: 30427748
[TBL] [Abstract][Full Text] [Related]
18. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
[TBL] [Abstract][Full Text] [Related]
19. Analysis of plasmid-mediated quinolone resistance genes in clinical isolates of the tribe Proteeae from Argentina: First report of qnrD in the Americas.
Albornoz E; Lucero C; Romero G; Rapoport M; Guerriero L; Andres P; ; Galas M; Corso A; Petroni A
J Glob Antimicrob Resist; 2014 Dec; 2(4):322-326. PubMed ID: 27873695
[TBL] [Abstract][Full Text] [Related]
20. Conjugal transfer of PMQR from uropathogenic E.coli under high ciprofloxacin selection pressure generates gyrA mutation.
Basu S; Mukherjee M
Microb Pathog; 2019 Jul; 132():26-29. PubMed ID: 30999022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
